Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by bionicjoeon Oct 14, 2018 8:55am
65 Views
Post# 28796720

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Wow...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Wow...Settle the financial uncertainty first and then you'll find the market will be more receptive as all the pieces needed for a phase 2 trial start clicking into place. Maybe if that happens posters will get back to the business of making money and leave discussions about climate control for those that have nothing better to do with their time. The company is doing shareholders a disservice by not addressing how they intend to pay for the start of treatment for the phase 2 trial when their refinancing efforts have only returned 1/10th of the necessary cash required. It is not good enough for investors to speculate that a white knight will come riding in to solve all their financial problems. Are they uncommunicative because they are working on a solution or are they out of ideas? You need to know.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities